Daily Cardiology Research Analysis
Three cardiology studies stand out today: a common, assay-agnostic high-sensitivity troponin change algorithm (3C) that matches ESC algorithms while improving operational effectiveness; a large US registry analysis showing direct oral anticoagulants after TAVR are associated with lower bleeding, mortality, and stroke versus warfarin; and a meta-analysis of 16 sham-controlled RCTs confirming renal denervation produces small but consistent blood pressure reductions with low complication rates.
Summary
Three cardiology studies stand out today: a common, assay-agnostic high-sensitivity troponin change algorithm (3C) that matches ESC algorithms while improving operational effectiveness; a large US registry analysis showing direct oral anticoagulants after TAVR are associated with lower bleeding, mortality, and stroke versus warfarin; and a meta-analysis of 16 sham-controlled RCTs confirming renal denervation produces small but consistent blood pressure reductions with low complication rates.
Research Themes
- Assay-agnostic cardiac troponin algorithms for MI rule-in/rule-out
- Anticoagulation strategy after TAVR (DOAC vs warfarin)
- Device-based hypertension therapy (renal denervation) efficacy and safety
Selected Articles
1. A Common Algorithm for Cardiac Troponin to Rule Out and Rule in Acute Myocardial Infarction.
In 5,011 ED patients with suspected MI across three hs-cTn assays, a common change-criteria (3C) algorithm achieved diagnostic accuracy comparable to ESC rule-in/rule-out pathways. 3C improved operational effectiveness for hs-cTnI (83–89% vs 64–75% for ESC) and ruled-in some MIs that ESC algorithms ruled out, while remaining assay-agnostic and sampling-interval independent.
Impact: Provides a unified, assay-agnostic hs-cTn change strategy that can simplify MI triage and harmonize practice across platforms. The operational gains for hs-cTnI could reduce ED congestion and time to decision.
Clinical Implications: Hospitals can consider implementing the 3C algorithm as an assay-agnostic alternative to ESC pathways, especially when multiple hs-cTn platforms are in use. Expect operational benefits for hs-cTnI; validate locally for hs-cTnT where effectiveness was not superior.
Key Findings
- Across 5,011 patients (MI prevalence 16.1%), 3C had sensitivity/specificity comparable to ESC algorithms.
- 3C improved effectiveness for hs-cTnI (83.2–88.8%) versus ESC (64.4–74.5%) but not for hs-cTnT.
- 3C ruled in additional MI cases that ESC pathways ruled out, without dependence on sampling interval.
Methodological Strengths
- Prospective cohorts with three different hs-cTn assays and standardized comparisons to ESC pathways
- Robust performance metrics with net reclassification and effectiveness analyses
Limitations
- Not a randomized comparison; potential contextual and workflow differences across sites
- hs-cTnT effectiveness was not superior to ESC; external validation needed across vendors
Future Directions: Prospective implementation studies assessing time-to-decision, ED throughput, and clinical outcomes across diverse hs-cTn platforms; vendor-specific calibration and health-economic evaluations.
BACKGROUND: A limitation of diagnostic algorithms in patients with suspected myocardial infarction (MI) is the requirement for assay-specific high-sensitivity cardiac troponin (hs-cTn) cutoff concentrations and change criteria. In this study we evaluated a common change criteria algorithm (3C) for hs-cTn and compared it with established algorithms for the rule out and rule in of MI. METHODS: We applied the 3C algorithm in 2 prospective cohort studies (with 3 different hs-cTn assays) of patients who presented to the emergency department with suspected MI who had serial hs-cTn results available. Diagnostic performance measures (sensitivity, specificity, predictive values, likelihood ratios) for MI were obtained for the 3C (change criteria > |3| ng/L for < 10 ng/L, > |30|% between 10 and 100 ng/L, and > |15|% for > 100 ng/L), and the European Society of Cardiology (ESC) algorithms for rule in and rule out. Confusion matrices, net reclassification improvement, and effectiveness (percentage rule in and rule out) analyses were also performed. RESULTS: In 5011 patients, the MI prevalence was 16.12% (n = 811). Comparable diagnostic accuracy in terms of sensitivity, specificity, and predictive values were observed between the 3C and ESC algorithms. Direct comparison of the algorithms via net reclassification improvement showed no decisive advantage for either algorithm. Confusion matrices for all 3 assays for the 0- and/or 1-hour and 0- and/or 2-hour sampling identified that the 3C ruled in more patients with an MI who were ruled out using the ESC algorithm. Effectiveness was higher for 3C (83.2%-88.8%) vs ESC (64.4%-74.5%) for hs-cTnI but not for hs-cTnT (64.5%-71.8% vs 72.4%-80.6%, respectively). CONCLUSIONS: The 3C algorithm offers a uniform, assay agnostic alternative to established algorithms, independent of timing of serial sampling. CLINICAL TRIAL REGISTRATIONS: NCT02355457, ACTR,12611001069943, ANZCTR12610000766011, and ANZCTR12613000745741.
2. Clinical outcomes of direct oral anticoagulant versus warfarin after transcatheter aortic valve replacement: From the STS/ACC TVT registry.
In 29,142 TAVR recipients requiring oral anticoagulation, DOAC use was associated with lower 1-year hospitalized bleeding (11.8% vs 15.2%), all-cause mortality (15.5% vs 17.5%), and, after adjustment, lower stroke risk compared with warfarin. DOAC use increased over time and surpassed warfarin by 2018.
Impact: Largest real-world comparative analysis to date supports DOACs over warfarin post-TAVR, informing guideline updates and prescribing patterns for a rapidly growing population.
Clinical Implications: In TAVR patients with an indication for long-term anticoagulation, a DOAC may be preferred over warfarin to reduce bleeding and mortality, barring contraindications or drug interactions. Shared decision-making is warranted until RCTs confirm causality.
Key Findings
- Among 29,142 TAVR patients on OAC, DOAC use (n=10,973) rose steadily and exceeded warfarin by 2018.
- At 1 year, DOACs had lower hospitalized bleeding (11.8% vs 15.2%) and all-cause mortality (15.5% vs 17.5%).
- Adjusted hazard ratios favored DOACs for bleeding (HR 0.49), mortality (HR 0.61), and stroke (HR 0.86), all P<.001.
Methodological Strengths
- Large national registry linked with claims data enabling robust outcome capture
- Multivariable Cox modeling and temporal trend analysis
Limitations
- Observational design with residual confounding and treatment selection bias
- Indications, dosages, and adherence details not randomized; bleeding definitions reliant on hospitalization coding
Future Directions: Randomized trials comparing DOACs versus warfarin post-TAVR across renal function strata and concomitant antiplatelet use; head-to-head comparisons among DOAC agents; cost-effectiveness analyses.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) recipients frequently have an indication for long-term oral anticoagulation, including atrial fibrillation or systemic thromboembolic disease. It remains unclear if there are differences in safety and effectiveness between direct oral anticoagulants (DOAC) and warfarin in this patient population. METHODS: Clinical outcomes were compared between TAVR recipients receiving DOACs or warfarin using data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) registry linked with Centers for Medicare & Medicaid Services claims data. The analysis included patients from the TVT registry who underwent successful TAVR and were discharged on either a DOAC or warfarin between January 2013 and May 2018. The primary outcome was any bleeding requiring hospitalization from discharge to 1 year. Secondary outcomes included all-cause mortality and stroke from discharge to 1 year. Multivariable Cox proportional hazards regression models were used to compare these outcomes between the 2 groups. RESULTS: A total of 29,142 patients underwent TAVR and were discharged on oral anticoagulation, among whom 10,973 (37.7%) were discharged on a DOAC. The use of DOACs increased throughout the study period and exceed the use of warfarin by the final year (2018). The cumulative incidence of bleeding requiring hospitalization at 1 year (11.8% vs 15.2%, P < .001) and all-cause mortality (15.5% vs 17.5%, P < .001) was significantly lower in DOAC group while stroke (2.47% vs 2.39%, P = .64) was not statistically different between groups. In an adjusted model, the use of a DOAC as opposed to warfarin was associated with a significantly lower risk of bleeding requiring hospitalization (adjusted hazard ratio 0.49, 95% confidence interval 0.43-0.56), all-cause mortality (adjusted hazard ratio 0.61, 95% confidence interval 0.57-0.66), and stroke (adjusted hazard ratio 0.86, 95% confidence interval 0.81-0.92) (all P < .001). CONCLUSIONS: In this analysis of TAVR recipients discharged on oral anticoagulation in a large U.S. registry, the use of a DOAC rather than warfarin was associated with a lower risk of bleeding requiring hospitalization, all-cause mortality, and stroke from discharge to 1 year. Future randomized studies will be necessary to establish the optimal choice of anticoagulant in TAVR patients.
3. Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta-Analysis of Sham-Controlled Randomized Clinical Trials.
Across 16 sham-controlled RCTs (n≈2,819), RDN lowered office SBP by ~4.3 mmHg and ambulatory SBP/DBP by smaller margins without increasing severe complications (0–2%). Despite high heterogeneity and very low GRADE certainty for most outcomes, these data support RDN as a viable adjunct/alternative for uncontrolled or resistant hypertension.
Impact: Synthesizes the highest level comparative evidence (sham-controlled RCTs) in a contentious field, clarifying magnitude of benefit and safety and informing guideline deliberations.
Clinical Implications: For patients with uncontrolled/resistant hypertension despite medications, RDN can be considered to achieve modest additional BP reductions with low severe complication rates. Shared decision-making should include discussion of modest effect sizes and low certainty of evidence.
Key Findings
- RDN reduced office SBP by −4.26 mmHg (95% CI −5.68 to −2.84) versus sham across 16 RCTs.
- Ambulatory 24-h SBP/DBP reductions were −2.63/−1.27 mmHg; daytime SBP/DBP also decreased.
- Severe complications were low (0–2%) and not increased versus sham; heterogeneity high; GRADE certainty very low for most outcomes.
Methodological Strengths
- Restriction to sham-controlled RCTs with random-effects modeling
- Use of GRADE to transparently rate certainty of evidence
Limitations
- High heterogeneity across trials and devices; varying medical therapy backdrops
- Very low certainty for many outcomes limits strength of recommendations
Future Directions: Head-to-head device comparisons, standardized concomitant therapy protocols, long-term cardiovascular outcome trials, and identification of responders via physiological phenotyping.
BACKGROUND: Although some guidelines recommend Renal denervation (RDN) as an alternative to anti-HTN medications, there are concerns about its efficacy and safety. We aimed to evaluate the benefits and harms of RDN in a systematic review and meta-analysis of sham-controlled randomized clinical trials (RCT). METHODS: Databases were searched until September 10th, 2024, to identify RCTs evaluating RDN for treating URH versus sham control. The primary outcomes were the change in office and ambulatory 24-h systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes were changes in daytime and nighttime SBP and DBP, home BP, number of anti-HTN drugs, and related complications. Mean differences (MD) and relative risks (RR) described the effects of RDN on BP and complications, respectively, using random effects meta-analyses. GRADE methodology was used to assess the certainty of evidence (COE). RESULTS: We found 16 included sham-controlled RCTs [RDN (n = 1594) vs. sham (n = 1225)]. RDN significantly reduced office SBP (MD -4.26 mmHg, 95% CI: -5.68 to -2.84), 24 h ambulatory SBP (MD -2.63 mmHg), office DBP (MD -2.15 mmHg), 24-h ambulatory DBP (MD -1.27 mmHg), and daytime SBP and DBP (MD -3.29 and 2.97 mmHg), compared to the sham. The rate of severe complications was low in both groups (0%-2%). The heterogeneity was high among most indices, and CoE was very low for most outcomes. CONCLUSION: RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.